Alnylam Pharmaceuticals, Inc. and Akshay K. Vaishnaw, M.D., Ph.D. entered into a letter agreement, whereby Dr. Vaishnaw will leave his current position as President of the Company and transition to a part-time role as Chief Innovation Officer, effective October 2, 2023.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
149.2 USD | -1.34% | -1.14% | -22.28% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-22.28% | 19.13B | |
+30.87% | 50.85B | |
+1.30% | 42.82B | |
+48.77% | 42.03B | |
-4.22% | 29.55B | |
+10.88% | 26.11B | |
+7.57% | 13.05B | |
+26.80% | 12.16B | |
+23.00% | 12.08B | |
-6.02% | 11.58B |
- Stock Market
- Equities
- ALNY Stock
- News Alnylam Pharmaceuticals, Inc.
- Alnylam Pharmaceuticals, Inc. Announces Management Changes, Effective October 2, 2023